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Abstract
Malnutrition, anemia and increased atherosclerosis are the main causes of mortality in hemodialysis
patients. Therapies designed to improve the disorders might therefore be expected to improve
outcome. The effects of Nandrolone Decanoate (ND), in 64 stable hemodialysis patients, were
studied with respect to the following parameters: nutritional status, hematological indexes, lipid
profiles including serum levels of lipoprotein(a) [Lp(a)] in terms of differences in apolipoprotein(a)
[apo(a)]. The patients were treated with ND at dose of 100 mg/I.M./week for 4 months. After 2
and 4 months of treatment the elevations in the serum levels of albumin (p < 0.0001), creatinine (p
< 0.009), hemoglobin (p < 0.03), hematocrit (p < 0.03), cholesterol (p = 0.007) and triglyceride (p
< 0.04) were noticed. Marked decrease in the concentration of high-density lipoprotein cholesterol
(p = 0.007) and Lp(a) (p < 0.0001) were also found. These effects after 2 months of treatment
withdrawal were relatively constant. By dividing patients according to the baseline Lp(a) levels and
molecular weight of apo(a) isoform, it was noticed that the decrease in serum Lp(a) was significant
in patients with high Lp(a) (>30 mg/dl) than those of with low Lp(a) (<30 mg/dl), irrespective of
apo(a) molecular weight. It may be suggested that, ND has beneficial effect on nutritional status and
treatment of anemia in hemodialysis patients. In spite the adverse effect of ND on lipid profile, it
decreases Lp(a) mostly in patients with high serum Lp(a) preferently by the effect on apo(a) gene
transcriptional activity.
Introduction
It is well-recognized that in chronic hemodialysis patients
the rate of mortality is higher than that of general popula-
tion [1,2]. The cause of discrepancy is probably multifac-
torial, but malnutrition, anemia, hypoalbuminemia,
reduced muscle mass and increased atherosclerosis are
common in dialysis patients [1-3]. Therapies designed to
improve the nutritional status, control of anemia and
atherosclerosis of hemodialysis patients might therefore
be expected to improve outcome [2,4]. Anabolic agents,
such as human growth hormone (HuGH) can improve
nitrogen balance, reduces urea generation and protein cat-
abolic rate in long term hemodialysis patients. However
HuGH is expensive, can exacerbate hyperglycemia and
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for anabolism [2].
The anemia of renal failure responses, directly to treat-
ment with erythropoietin [5]. Because of the relatively
high cost of recombinant human erythropoietin, the use
of Nandrolone Decanoate (ND) a non-17alpha-alkylated
androgen has been suggested instead of the above men-
tioned hormone [2,6]. Many studies have shown that ND
not only increased RBC production, but also prolonged
RBC survival [7]. In spite that the drug is associated with
high incidence of adverse effects including acne, viriliza-
tion, abnormal liver function, discomfort from intramus-
cular injection [7], It can increase weight, triceps skinfold
thickness, nitrogen balance and bone mineral density
[2,7]. Moreover a reduction in the level of atherogenic
lipoprotein (a) [Lp(a)] particles following ND adminis-
tration to hemodialysis patients has been described [4].
Lp(a) is an important independent risk factor for athero-
sclerotic cardiovascular disease in general population as
well as in hemodialysis patients [8-10]. The lipoprotein
contributes at least partially to the increased cardiovascu-
lar risk seen in patients with renal failure [11]. Therefore
it is clinically important to reduce high serum Lp(a) by
intervention [12-14].
Lp(a) is a low-density lipoprotein particle in which apoli-
poprotein B-100 (apo B-100) linked by a single interchain
disulfide bridge to a unique glycoprotein apolipopro-
tein(a) [apo(a)] [13]. In contrast to apo B-100, which
remain relatively constant in molecular weight, apo(a),
under genetic control, ranges between 300 and 800 KD
[15-17]. Utermann et al. detected 6 polymorphs with dif-
ferent in sizes and a null variant of apo(a) [18]. The size
of the apo(a) phenotypes F, B, S1, S2, S3 and S4 were
inversely associated to plasma concentrations of Lp(a)
and family studies showed that a series of autosomal alle-
les at one locus are involved in determining both apo(a)
size and Lp(a) concentration [19,20].
It is now demonstrated that plasma levels of Lp(a) are
controlled by synthesis rather than by catabolism [21,22].
There are limited data on how diet and drugs effect
plasma Lp(a) levels [23]. The purpose of this study was to
analyze the effect of ND on nutritional status, hematolog-
ical parameters, lipid profiles and serum levels of Lp(a) in
terms of differences in apo(a) isoforms in patients on
hemodialysis.
Subjects and Methods
We studied 70 Iranian patients under maintenance hemo-
dialysis between Jun 2002 and Dec 2003. Malnutrition,
active hepatitis and benign prostatic hypertrophy (in
males) were among the exclusion criteria. Six patients
were lost to follow-up (3 died from cardiac arrest, 2
received kidney transplant and 1 for abnormal liver func-
tion). Sixty four patients (47 male and 17 female), mean
age of 63 ± 12 years completed the study period. The eti-
ology of end-stage renal disease was diabetic nephropathy
(n = 10), chronic glomerulonephritis (n = 17), polycystic
disease (n = 5), urological problems (n = 5), chronic inter-
stitial nephropathy (n = 4) and unknown (n = 23). All the
patients underwent hemodialysis (4 hours) two to three
times per week using cellulosic membrane. The dialysis
schedule was not modified during period of the study.
After taking of informed consent from the patients, ND
100 mg/I.M. was given weekly for 4 months. Before
hemodialysis sessions fasting venous blood samples were
collected before the start of ND treatment, at 2, 4 months
during the treatment and 2 months after withdrawing of
treatment.
Hemoglobin (Hb) and hematocrit (Hct) were measured
by cell counter, and serum levels of total cholesterol (C),
triglyceride (TG), high – density lipoprotein cholesterol
(HDL-C), albumin (Alb) and creatinine (Cr) in the col-
lected samples were determined by using commercial rea-
gents (Randox) in an automated chemical analyzer
(Cobas Mira). The serum levels of Lp(a) were assayed by
commercially available immunoturbidimetric kit using
the same analyzer. The apo(a) phenotypes were deter-
mined by sodium dodecyl sulfate-polyacrylamide / agar-
ose gel electrophoresis and immunoblotting with
monoclonal apo(a) antibodies [24,25]. Apo(a) isoform
sizes were determined by comparison of their sizes with
an apo(a) standard (Immuno-AG) electrophoresed on
each gel which contained 5 different isoforms. Low
molecular weight (LMW) apo(a) phenotypes included all
subjects who had at least one of the isoforms F, B, S1 or
S2, whereas the high molecular weight (HMW) apo(a)
phenotypes included all subjects with only S3 or S4 iso-
forms or with null type [21,25,26].
SPSS 11 for window program was used to perform statis-
tical analysis by computer. Results are expressed as mean
± SD. Paired t-test and wilcoxon signed ranks test as
appropriate were used to assess significancy of differences
between base and 2 months after withdrawing treatment.
Comparisons analysis between base, two and post of
treatment values were performed using multiple compar-
ison in one-way ANOVA and Friedman tests. All correla-
tion were evaluated by liner regression and the statistical
significance was set at p < 0.05.
Results
The changes in serum levels of Alb, Cr, C, TG, HDL-C and
Lp(a) and blood concentration of Hb and Hct following 2
and 4 months treatment with ND are shown in Table 1.
Serum levels of Alb and Cr were determined to assess thePage 2 of 6
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months treatment significant elevation in the serum levels
of the both parameters was noticed (p < 0.0001 and p <
0.009 respectively). Marked increase of Hb and Hct, with-
out increasing of erythropoietin dose, was also found after
2 and 4 months treatment (p < 0.03 in all the cases). The
effect of ND on the lipid profile was evaluated by measur-
ing serum levels of C, TG and HDL-C in samples collected
before and two and four months after the treatment.
Marked increase in the mean ± SD levels of C (P = 0.007),
TG (p < 0.04) and significant decrease in the concentra-
tion of HDL-C (P = 0.007) was detected in all the samples
obtained after the treatment.
Serum Lp(a) concentration before the start of ND treat-
ment was 40.6 ± 24.2 mg/dl and reduced to 33.1 ± 19.2
mg/dl and 31.3 ± 17.2 mg/dl after 2 and 4 months of
treatment with ND respectively (p < 0.0001).
To certain the effect of ND on the above parameters after
2 months of treatment withdrawal, evaluation of the
above parameters was repeated. As shown in Table 1,
reduction of the previously elevated C and increased the
concentration of the previously reduced HDL-C was
noticed, although they did not reach to the baseline and
C was significantly higher and HDL-C was still signifi-
cantly lower than the basal values (p < 0.0001 and p =
0.004 respectively). Although TG was decreased after ND
withdrawal, as compared after ND therapy, no meaning-
ful changes comparing with basal value was detected (p =
0.085).
Reduction was also noticed in the both of Hb concentra-
tion and Hct (p = 0.001 in all the cases) and also those of
Alb and Cr (p = 0.001 and p = 0.008 respectively), but still
all of them were maintained higher than those of basal
values. The mean ± SD levels of Lp(a) after withdrawal of
ND treatment slightly increased from 31.3 ± 17.2 mg/dl to
33.3 ± 21.8 mg/dl. However, Lp(a) concentration still was
significantly lower than that of basal value (p < 0.0001).
To determine the suppressive effect of ND on serum levels
of Lp(a) according to the baseline Lp(a) levels and the
molecular weight of apo(a) isoforms, after 4 months treat-
ment, the patients were divided into two groups according
their basal Lp(a) levels [13,27]: less than and higher than
30 mg/dl groups, and the mean ± SD values of reduction
in the each group were categorized in the following four
patients groups: high Lp(a) with HMW phenotypes (n =
15), high Lp(a) with LMW phenotypes (n = 22), low Lp(a)
with HMW phenotypes (n = 20) and low Lp(a) with LMW
phenotypes (n = 7). As are represented in Table 2 signifi-
cant decrease in Lp(a) concentration was observed in the
high Lp(a) with HMW and, high Lp(a) with LMW groups
Correlation between basal serum Lp(a)concentration and decrease in serum Lp(a) fter 4 onths f ND treatme t [delta Lp(a)] in patie ts wi h high serum Lp(a) conce tra ion in HMW mol c lar weight g o psFigure 1
Correlation between basal serum Lp(a)concentration and 
decrease in serum Lp(a) after 4 months of ND treatment 
[delta Lp(a)] in patients with high serum Lp(a) concentration 
in HMW molecular weight groups. delta Lp(a) = Lp(a) [after 
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Lp(a) levels in the other two groups were not marked (p >
0.1 and p > 0.2 respectively). The correlation between the
baseline Lp(a) levels and the degree of decreased Lp(a)
after 4 months of ND treatment [delta Lp(a)] in patients
with high serum Lp(a) concentration according to apo(a)
molecular weight were analyzed in the patients with high
serum Lp(a) concentration. Interestingly significant corre-
lation in both high Lp(a) with HMW phenotypes (r =
0.832, p < 0.01) (fig. 1) and high Lp(a) with LMW pheno-
types (r = 0.713, p < 0.01) patients groups were noticed
(fig. 2).
Discussion
There are limited data on how diet and drugs affect
plasma Lp(a) levels. Lp(a) levels are unaffected by lipid
lowering dietary treatment, and are even increased by die-
tary trans fatty acids [23,28,29]. Furthermore, the Lp(a)
serum level is unaffected by most lipid – lowering drugs
[23,30-32]. Neither treatment with HMG-CoA reductase
inhibitors, nor fibrate drugs have resulted in significant
lowering of Lp(a) levels [33]. In the present study the
effect of ND therapy on nutritional status, hematological
parameters and lipid profiles with emphasis on Lp(a)
were evaluated in 64 stable hemodialysis patients. Malnu-
trition is a highly prevalent and clinically significant prob-
lem in chronic hemodialysis patients. It has been reported
that low levels of Alb and Cr were associated with a
significantly greater risk of hemodialysis patients' mortal-
ity. Therefore therapeutic agents which increase Alb and
Cr levels may decrease mortality in these patients [1,2].
Many studies have shown that treatment with ND resulted
in significant increase in serum Alb and Cr levels [1,7]. We
also observed that treatment with ND increases the con-
centrations of the Alb and Cr and after the androgen with-
drawal, levels of the parameters maintained at levels
higher than the basal values at before of treatment. The
findings suggest that ND treatment has beneficial effects
on nutritional status in hemodialysis patients.
It has been suggested that administration of androgen
also has beneficial effect on erythropoiesis in patients on
regular hemodialysis [2,5-7,34,35]. We analyzed the effect
of ND on hematological factors in hemodialysis patients.
Hb and Hct values raised significantly with respect to
basal values during the study although dose of the recom-
binant human erythropoietin were not changed during
the therapy with ND. Moreover after discontinuing use of
Table 1: Changes of nutritional, hematological and lipid profile before the start of ND treatment, at, 2, 4 months during the treatment 
and 2 months after withdrawing treatment in 64 hemodialysis patients.
Basal (Mean ± SD) 2 months (Mean ± SD) 4 months (Mean ± SD) ND withdrawal 2 months 
(Mean ± SD)
Albumin(g/dl) 3.6 ± 0.8 3.9 ± 0.8 4.3 ± 1.0 (p < 0.0001)* 4.0 ± 1.0 (p = 0.001)**
Creatinine(mg/dl) 9.5 ± 3.4 10.7 ± 3.8 11.4 ± 3.4 (p < 0.009)* 10.3 ± 3.4 (p = 0.008)**
Hemoglobin(g/dl) 9.2 ± 2.2 9.9 ± 2.2 10.2 ± 2.1 (p < 0.03)* 9.9 ± 1.8 (p = 0.001)**
Hematocrit (%) 28.2 ± 6.7 30.2 ± 6.6 31.3 ± 6.4 (p < 0.03)* 30.4 ± 5.5 (p = 0.001)**
Cholesterol(mg/dl) 179.4 ± 38.5 196.1 ± 38.8 200.1 ± 39.1 (p = 0.007)* 197.6 ± 35.5 (p < 0.0001)**
HDL-C(mg/dl) 37.5 ± 4.3 36.4 ± 3.7 35.4 ± 3.0 (p = 0.007)* 36.3 ± 3.4 (p = 0.004)**
Triglyceride(mg/dl) 178.7 ± 85.9 180.4 ± 73.3 187.6 ± 70.7 (p < 0.04) *** 181.8 ± 64.6 (p = 0.085)* ***
Lp(a)(mg/dl) 40.6 ± 24.2 33.1 ± 19. 2 31.3 ± 17.2 (p < 0.0001) *** 33.3 ± 21.8 (p < 0.0001)* ***
*, Comparison analysis between base, two and post of treatment values were performed using multiple comparisons by one-way ANOVA. **, 
Paired t-test was used to assess significancy of differences between base and 2 months after withdrawing treatment. ***, Comparison analysis 
between base, two and post of treatment values were performed using Friedman test. ****, Wilcoxon signed ranks test was used to assess 
significancy of differences between the base and 2 months after withdrawing of treatment.




High Lp(a) [mg/dl] 
(mean ± SD)
Low Lp(a) [mg/dl] 
(mean ± SD)
Basal 4 months *p value Basal 4 months *p value
HMW 42.1 ± 10.6 27.1 ± 5.9 P = 0.001 18.4 ± 7.2 17.1 ± 5.9 p > 0.1
LMW 65.6 ± 19.5 50.2 ± 14.4 P < 0.0001 22.7 ± 7.4 21.9 ± 7.8 p > 0.2
*, Wilcoxon signed ranks test.Page 4 of 6
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their levels still significantly were higher than basal val-
ues. Our results suggest that ND can be used successfully
in the treatment of anemia in hemodialysis patients.
Many studies concluded that androgen therapy is associ-
ated with high incidence of adverse effect in lipid profiles
[4,5,34] while others have shown that ND has no marked
effect on the lipid profile [2]. In this study evaluating the
effect of the drug on lipid profiles showed significantly
increase in C and marked decrease in HDL-C levels, with-
out significant changes in TG level. Although after with-
drawal ND therapy the levels of C decreased and that of
HDL-C increased, but the levels of both parameters were
still significantly different from those of the basal values.
The data confirm the finding of the others that, treatment
with ND is associated with adverse effect on serum lipid
profiles [4,34]. We believe that the accompanying of lipid
lowering agents during ND administration in hemodialy-
sis patients maybe clinically useful and deserves another
study.
In our investigation significant reduction in the levels of
Lp(a) in hemodialysis patients after 4 months treatment
with ND was observed. Lp(a) is largely genetically deter-
mined by the rate of production of apo(a) and the protein
levels mostly controlled by both synthesis and secretion
[36-40]. The synthesis of apo(a) depends on the expres-
sion of apo(a) mRNA in hepatocytes, which is regulated
by transcriptional activity of the apo(a) gene. The secre-
tion of apo(a) by hepatocytes in turns is affected by the
molecular weight of the apo(a) isoforms [41,42]. For
comparing the transcriptional activity of the apo(a) gene
in term of apo(a) molecular weight, all patients were clas-
sified into the following four groups: 1-high Lp(a) con-
centration with HMW isoforms. 2-high Lp(a)
concentration with LMW isoforms. 3-low Lp(a) concen-
tration with HMW isoforms. 4-low Lp(a) concentration
with LMW isoforms [13]. Because groups with high Lp(a)
concentration have higher transcriptional activity than
groups with low Lp(a) levels in same molecular weight
isoforms, it is conceivable that, group 1 has a higher tran-
scriptional activity than group 3, and group 2 has higher
transcriptional activity than group 4 [13]. Results have
shown that ND lowered serum Lp(a) concentration more
effectively in patients with high Lp(a) in both HMW and
LMW isoforms (group 1, 2), and the decreased values for
serum Lp(a) are correlated with the pre-treatment (basal
levels) of serum Lp(a) in both groups. Because it was
established that, the secretory efficiencies of apo(a) in the
same molecular weight isoforms are likely to be similar
[13], a different in Lp(a) reduction in the same molecular
weight isoforms (group 1, 3 and group 2, 4) would repre-
sent a different in transcriptional activity of apo(a) gene.
Therefore it may be suggested that, ND lowers serum
Lp(a) concentration preferentially in patients with high
serum Lp(a) levels by effect on apo(a) gene transcription
rather than effect on secretory efficiency of apo(a) in
hemodialysis patients. In conclusion, ND administration
has beneficial effects on nutritional status and treatment
of anemia in hemodialysis patients. In spite of the fact
that the drug has adverse effect on the lipid profiles, it
reduces the level of Lp(a) mostly in patients with high
Lp(a) levels irrespective of apo(a) isoform size. Further
studies in a large number of patients are needed to con-
firm this hypothesis.
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